Busulfan
- TRADE NAMES: Citosulfan; Leukosulfan; Mablin; Misulban; Myleran (GSK)
- INDICATIONS: Chronic myelogenous leukemia, bone marrow disorders
- CLASS: Alkylating agent
- HALF-LIFE: 3.4 hours (after first dose)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Aldesleukin, Itraconazole, Metronidazole, Voriconazole
PREGNANCY CATEGORY: D
LEUKEMOGENESIS and PANCYTOPENIA
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 08/02/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric